Jupiter Topco LLC Acquires New Position in Sotera Health Company $SHC

Jupiter Topco LLC acquired a new stake in Sotera Health Company (NASDAQ:SHC) during the 2nd quarter, HoldingsChannel reports. The firm acquired 8,402,106 shares of the company’s stock, valued at approximately $149,137,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Sotera Health in the second quarter worth $428,635,000. Sculptor Capital LP boosted its position in Sotera Health by 3.4% during the first quarter. Sculptor Capital LP now owns 21,717,728 shares of the company’s stock valued at $311,432,000 after purchasing an additional 717,728 shares during the last quarter. Vanguard Group Inc. grew its stake in Sotera Health by 16.7% in the fourth quarter. Vanguard Group Inc. now owns 19,228,375 shares of the company’s stock valued at $339,189,000 after purchasing an additional 2,756,583 shares in the last quarter. Sachem Head Capital Management LP grew its stake in Sotera Health by 47.2% in the fourth quarter. Sachem Head Capital Management LP now owns 11,645,000 shares of the company’s stock valued at $205,418,000 after purchasing an additional 3,735,000 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in Sotera Health by 35.3% in the 1st quarter. Janus Henderson Group PLC now owns 9,162,191 shares of the company’s stock worth $131,413,000 after purchasing an additional 2,390,132 shares during the last quarter. Hedge funds and other institutional investors own 91.03% of the company’s stock.

Insider Activity at Sotera Health

In other Sotera Health news, insider Michael P. Rutz sold 150,000 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $18.84, for a total transaction of $2,826,000.00. Following the transaction, the insider owned 334,279 shares in the company, valued at $6,297,816.36. This trade represents a 30.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Michael B. Jr. Petras sold 850,000 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $18.50, for a total value of $15,725,000.00. Following the transaction, the chairman owned 3,969,393 shares in the company, valued at approximately $73,433,770.50. This trade represents a 17.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 1,294,515 shares of company stock valued at $23,999,528. Corporate insiders own 15.36% of the company’s stock.

Sotera Health Price Performance

NASDAQ SHC opened at $19.54 on Thursday. Sotera Health Company has a fifty-two week low of $13.09 and a fifty-two week high of $19.85. The stock’s 50-day moving average is $17.98 and its two-hundred day moving average is $16.38. The company has a debt-to-equity ratio of 3.33, a current ratio of 2.80 and a quick ratio of 2.55. The firm has a market cap of $5.58 billion, a P/E ratio of 34.28 and a beta of 1.77.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.24 by $0.02. The company had revenue of $321.38 million during the quarter, compared to the consensus estimate of $309.70 million. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The firm’s revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.20 EPS. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. On average, analysts anticipate that Sotera Health Company will post 0.86 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on SHC. JPMorgan Chase & Co. raised their price target on Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Friday, August 7th. Barclays increased their price objective on Sotera Health from $19.00 to $22.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. Piper Sandler reaffirmed an “overweight” rating and set a $25.00 price objective (up from $22.00) on shares of Sotera Health in a research report on Friday, August 7th. UBS Group set a $19.00 target price on shares of Sotera Health in a research note on Wednesday, June 24th. Finally, The Goldman Sachs Group began coverage on shares of Sotera Health in a research report on Friday, June 5th. They issued a “buy” rating and a $20.00 target price for the company. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Sotera Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $21.50.

Sotera Health Company Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.